Clinical-Stage Neuroscience

An Epic Leap
For Mental Health

Developing innovative new chemical entities that transform the treatment paradigm of psychiatric disease — moving beyond symptom management toward rapid-acting, durable therapies.

Our Programs View Pipeline
Phase 3
Phase 2
Phase 1
IND
Bretisilocin
Blixeprodil
Neuroplastogens
GM-3009
M1/M4 Agonist
5+
Programs
NCE
Novel Chemical Entities
Multimodal
Discovery Platform
1×
Asset Acquired by AbbVie
Our Mission

Beyond Symptom Management

Current psychiatric treatments often mask symptoms rather than addressing underlying neurobiological roots. Gilgamesh is building a new class of precision therapies that engage the brain's own plasticity mechanisms to produce lasting change.

Our deep expertise in medicinal chemistry, combined with an multimodal translational platform, enables us to design and optimize novel molecules with unprecedented speed — targeting the mechanisms that matter most.

"The brain has a remarkable capacity to rewire itself. We are learning to speak its language — with molecules designed not to silence, but to restore." — Jonathan Sporn, MD · Founder & CEO
Our Programs

Five Therapeutic Frontiers

Full Pipeline →
01

Bretisilocin (GM-2505)

Short-Acting 5-HT2AR Agonist
Acquired by AbbVie

Our first asset to advance to Phase 2 — a rapid-acting 5-HT2AR agonist with a 2-hour treatment window. Its acquisition by AbbVie validates our NCE discovery platform.

Rapid-Acting2-Hour DurationPhase 2
Depression
02

Blixeprodil (GM-1020)

NMDAR Antagonist

An orally bioavailable NMDAR antagonist with rapid antidepressant effects and low dissociation — enabling potential at-home use and removing the IV monitoring burden of ketamine.

OralRapid-ActingLow DissociationPhase 2
Depression
03

Neuroplastogens

Non-Hallucinogenic · AbbVie Partnership

A novel series of non-hallucinogenic neuroplastogens promoting structural and functional brain plasticity — developed in partnership with AbbVie for depression and anxiety.

Non-HallucinogenicNeuroplasticity
Depression & Anxiety
04

GM-3009

Safer Ibogaine Analog

Structurally optimized ibogaine analogs with improved cardiac safety and maintained efficacy — addressing opioid use disorder, PTSD, and traumatic brain injury.

Cardiac SafetyImproved Efficacy
OUD · PTSD · TBI
05

M1/M4 Agonist

Muscarinic Receptor Agonist

A single oral agent with refined M1/M4 selectivity and a significantly reduced peripheral side effect profile, offering a cleaner therapeutic window for schizophrenia.

OralReduced Side Effects
Schizophrenia
Platform

AI-Powered Discovery Behind Every Program

Deep medicinal chemistry expertise combined with computational modeling accelerates our NCE pipeline from concept to clinic.

See Full Pipeline →
Clinical Pipeline

Program Status

Five programs spanning depression, anxiety, addiction, and schizophrenia — all novel chemical entities designed in-house.

Program
Indication
Type
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
Bretisilocin (GM-2505)
Short-Acting 5-HT2AR Agonist · Acquired by AbbVie
Depression
NCE
Blixeprodil (GM-1020)
NMDAR Antagonist
Depression
NCE
Neuroplastogens
Non-hallucinogenic · AbbVie partner
Depression & Anxiety
NCE
GM-3009
Safer Ibogaine Analog
OUD · PTSD · TBI
NCE
M1/M4 Agonist
Muscarinic Receptor Agonist
Schizophrenia
NCE
Complete
Active stage
Future
Acquired by AbbVie
Discovery Platform

Where Chemistry Meets Intelligence

Our discovery and translational platform integrates medicinal chemistry expertise, neurocircuitry science, and deep neuroscience knowledge to accelerate the creation of novel precision psychiatric therapies.

The result: faster NCE identification, richer SAR data, and a compounding competitive advantage — as validated by AbbVie's acquisition of Bretisilocin.

Medicinal Chemistry
Expert-led SAR campaigns deliver best-in-class selectivity, pharmacokinetics, and safety for each NCE.
Translational Science
A state-of-the-art, neurocircuitry-focused platform that integrates behavioral, electrophysiological, molecular, and machine learning approaches to characterize psychoactive compounds and optimize drug candidates for improved clinical translation.
Clinical Execution
Rigorous trial design and hands-on operational expertise translate promising molecules into clear clinical proof-of-concept — as demonstrated by positive Phase 2a results for both bretisilocin and blixeprodil.
Leadership

World-Class Scientists & Leaders

A team of medicinal chemists, inventors, and drug development veterans from top academic and biopharmaceutical institutions, tackling the hardest mental health challenges facing the world today.

Jonathan Sporn, MD
Founder, CEO

25+ years in drug development at Pfizer and J&J. Assistant Professor of Psychiatry, Columbia University. Founder of Perception Neuroscience (acquired by ATAI Life Sciences). Research at Harvard and NIH.

Andrew Kruegel, PhD
Co-Founder, CSO

Medicinal chemist with 10+ years synthesizing and patenting psychedelic and ibogaine analogs. Discovered MOA of antidepressant Tianeptine. Founder & CSO of Kures Therapeutics (acquired by ATAI).

Jorge Quiroz, MD MBA
CDSO

20+ years in drug development at NIH, J&J, and Roche. Spans IND filings through NDA/sNDA for small molecules and gene therapy. Former BoD member of Perception Neuroscience.

Gerard Marek, MD PhD
CMO

25+ years in early clinical development. Asst. Professor of Psychiatry at Yale. Associate Director at Pfizer, Psychiatric CSO at Eli Lilly, Global Medical Lead at Astellas Pharma.

Laszlo Kiss, PhD
CBO & Head of Research

20+ years in drug discovery at Merck and Bristol-Myers Squibb. Leadership in corporate venture and business development at Pfizer and Biogen.

Yoni Falkson, MBA
COO

15+ years in commercial development, payer strategy, and product launches. Co-founder of SpringWorks Therapeutics. Commercial leadership at Pfizer and Regeneron.

Zoë Hughes, PhD
EVP of Biology & Translation

25+ years CNS drug discovery at GlaxoSmithKline, Wyeth, and Pfizer. Most recently VP Biology at Praxis Precision Medicine.

Latest News

Press & Announcements

Financing
Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies
→
Acquisition
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
→
Clinical Results
Gilgamesh Pharmaceuticals Announces Positive Topline Phase 2a Results for GM-2505 in Major Depressive Disorder (MDD)
→
Recognition
Gilgamesh Named on Fierce Biotech's 2024 Fierce 15
→
Partnership
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
→
Clinical Trial
Gilgamesh Announces Initiation of Phase 2a Trial of GM-1020 in Major Depressive Disorder
→
Grant Award
Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder
→
Clinical Trial
Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD Clinical Trial of GM-2505
→
Clinical Trial
Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020
→
Financing
Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments
→
Investor Perspective
Why We Invested in Gilgamesh (Again)
→
Partners & Collaborators

At the Forefront of Innovation

We collaborate with leading pharma companies and research institutions that share our commitment to transforming psychiatry.

AbbVie
Pharma Partner & Acquirer

Acquired our first asset Bretisilocin (GM-2505), validating our discovery platform. Ongoing partnership on the Neuroplastogen program for depression and anxiety.

NIDA
Research Funding

Supported by the National Institute on Drug Abuse, validating our science and approach to addiction programs including GM-3009 for OUD, PTSD, and TBI.

Columbia
Academic Research

Deep research partnership with Columbia University bringing world-class neuroscience expertise and translational insights to our discovery programs.

Backed by Notable Investors
Get In Touch

Partner With Us

We welcome conversations about partnerships, investment opportunities, licensing, and careers. If you share our vision for transforming psychiatry, we'd like to hear from you.

Contact Us View Pipeline